Literature DB >> 17692492

Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application.

Jhy-Wen Wu1, Lie-Chwen Lin, Shih-Chieh Hung, Chin-Wen Chi, Tung-Hu Tsai.   

Abstract

Silibinin is an herbal ingredient isolated from milk thistle. The aim of this study was to develop a simple liquid chromatographic system to assay silibinin in plasma and bile for pharmacokinetic study. Silibinin was given oral and intravenously. The plasma sample (25 microL) was vortex-mixed with 50 microL of internal standard solution (naringenin 10 microg/mL in acetonitrile) to achieve protein precipitation. Silibinin in the rat plasma and bile was separated using a reversed-phase C18 column (250 mm x 4.6 mm, 5 microm) with a mobile phase of acetonitrile -10 mM monosodium phosphate (pH 5.45 adjusted with orthophosphoric acid) (50:50, v/v) and the flow-rate of 1 mL/min. The UV detection wavelength was 288 nm. The concentration-response relationship from the present method indicated linearity over a concentration range of 0.5-100 microg/mL. Intra- and inter-assay precision and accuracy of silibinin fell well within the predefined limits of acceptability (<15%). An ultrafiltration method was used in this experiment and the protein binding of silibinin was 70.3+/-4.6%. After silibinin administration in rats, the disposition of silibinin in the plasma and bile fluid was due to rapid distribution and equilibration between the blood and hepatobiliary system, and the bile levels of unconjugated silibinin and total silibinin were greater than those in the plasma. The oral bioavailability of silibinin in rats was estimated to be 0.73%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692492     DOI: 10.1016/j.jpba.2007.06.026

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  36 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  An ex vivo approach to botanical-drug interactions: a proof of concept study.

Authors:  Xinwen Wang; Hao-Jie Zhu; Juliana Munoz; Bill J Gurley; John S Markowitz
Journal:  J Ethnopharmacol       Date:  2015-01-24       Impact factor: 4.360

3.  Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility.

Authors:  Rui-ling Duan; Xun Sun; Jie Liu; Tao Gong; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-12-20       Impact factor: 6.150

Review 4.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

5.  Enhanced bioavailability and hepatoprotective effect of silymarin by preparing silymarin-loaded solid dispersion formulation using freeze-drying method.

Authors:  Dong Yu Lim; Minyeong Pang; Jaehyeok Lee; Jihoon Lee; Ji-Hyeon Jeon; Jin-Hyang Park; Min-Koo Choi; Im-Sook Song
Journal:  Arch Pharm Res       Date:  2022-09-30       Impact factor: 6.010

6.  Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles.

Authors:  Noha Nafee; Dina M Gaber; Ahmed O Elzoghby; Maged W Helmy; Osama Y Abdallah
Journal:  Pharm Res       Date:  2020-04-14       Impact factor: 4.200

7.  Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma.

Authors:  Elizabeth Brandon-Warner; James A Sugg; Laura W Schrum; Iain H McKillop
Journal:  Cancer Lett       Date:  2009-11-08       Impact factor: 8.679

8.  Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Authors:  Chihiro Morishima; Margaret C Shuhart; Chia C Wang; Denise M Paschal; Minjun C Apodaca; Yanze Liu; Derek D Sloan; Tyler N Graf; Nicholas H Oberlies; David Y-W Lee; Keith R Jerome; Stephen J Polyak
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

9.  Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.

Authors:  Jessica Wagoner; Chihiro Morishima; Tyler N Graf; Nicholas H Oberlies; Elodie Teissier; Eve-Isabelle Pécheur; John E Tavis; Stephen J Polyak
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.

Authors:  Kathleen Köck; Ying Xie; Roy L Hawke; Nicholas H Oberlies; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-02-11       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.